Efficacy and safety of remimazolam tosylate in hysteroscopy: A randomized, single-blind, parallel controlled trial
- PMID: 34655087
- DOI: 10.1111/jcpt.13525
Efficacy and safety of remimazolam tosylate in hysteroscopy: A randomized, single-blind, parallel controlled trial
Abstract
What is known and objective: To compare the effectiveness and safety of remimazolam tosylate and propofol for hysteroscopy.
Methods: From November 2020 to June 2021, a total of 90 patients who underwent hysteroscopy were prospectively enrolled in this study. The patients were randomly assigned to three groups: propofol group (group A), low-dose remimazolam tosylate group (group B), and high-dose remimazolam tosylate group (group C), with 30 cases in each group. All cases received intravenous sufentanil 0.1ug/kg for analgesic preconditioning. Patients in group A were given 2 mg/kg propofol intravenously, and maintained at a rate of 5 mg/kg/h. Patients in groups B and C were given intravenous remimazolam tosylate 0.25 mg/kg. Group B was maintained with remimazolam tosylate at a rate of 0.48 mg/kg/h, while group C was at a rate of 0.6 mg/kg/h. The changes of heart rate (HR), mean arterial pressure (MAP) and saturation of peripheral oxygen (SpO2) were recorded after admission (T0), 1 min after anaesthesia (T1), dilation of the uterine cavity (T2), and the end of hysteroscopy (T3). In addition, Observer's Assessment of Alertness/Sedation Scale (OAA/S) at 1 min, 3 min, and 5 min after hysteroscopy, the incidence of adverse events, and the time from the end of the hysteroscopy to reach the discharge standard, were recorded.
Results and discussion: The success rate of sedation in each group was 100%. After administration, the adverse event incidence in group A was significantly higher than that in groups B and C (p < 0.05, respectively). Compared with propofol, remimazolam tosylate did not cause injection pain, had less impact on haemodynamics and caused less respiratory depression.
What is new and conclusion: Remimazolam tosylate and propofol have similar success rates for painless hysteroscopy, and both can provide safe and effective sedation. The safety of remimazolam tosylate for hysteroscopy appears to be better than that of propofol.
Keywords: hysteroscopy; propofol; remimazolam tosylate; sedation.
© 2021 John Wiley & Sons Ltd.
Similar articles
-
Efficacy and Safety of Remimazolam in Short Endoscopic Procedures: A Systematic Review and Meta-Analysis.Medicina (Kaunas). 2025 Mar 5;61(3):453. doi: 10.3390/medicina61030453. Medicina (Kaunas). 2025. PMID: 40142264 Free PMC article.
-
Remimazolam Tosylate Combined with Low-Dose Propofol Improves Sedation and Safety in Hysteroscopy.Drug Des Devel Ther. 2022 Nov 29;16:4101-4108. doi: 10.2147/DDDT.S390403. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36471692 Free PMC article. Clinical Trial.
-
Comparison of hypotension between propofol and remimazolam-propofol combinations sedation for day-surgery hysteroscopy: a prospective, randomized, controlled trial.BMC Anesthesiol. 2024 Oct 8;24(1):360. doi: 10.1186/s12871-024-02746-9. BMC Anesthesiol. 2024. PMID: 39379858 Free PMC article. Clinical Trial.
-
Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial.BMC Anesthesiol. 2021 May 20;21(1):156. doi: 10.1186/s12871-021-01373-y. BMC Anesthesiol. 2021. PMID: 34016045 Free PMC article. Clinical Trial.
-
Comparison of the Safety and Efficacy of Remimazolam and Propofol for Sedation in Adults Undergoing Colonoscopy: A Meta-Analysis of Randomized Controlled Trials.Medicina (Kaunas). 2025 Apr 1;61(4):646. doi: 10.3390/medicina61040646. Medicina (Kaunas). 2025. PMID: 40282937 Free PMC article.
Cited by
-
Comparison of oxygen reserve index according to the remimazolam or dexmedetomidine for intraoperative sedation under regional anesthesia-A single-blind randomized controlled trial.Front Med (Lausanne). 2023 Nov 15;10:1288243. doi: 10.3389/fmed.2023.1288243. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38034542 Free PMC article.
-
Effects of remimazolam combined with remifentanil on quality of recovery after ambulatory hysteroscopic surgery: a prospective, observational study.Anesth Pain Med (Seoul). 2024 Jan;19(1):44-53. doi: 10.17085/apm.23102. Epub 2024 Jan 30. Anesth Pain Med (Seoul). 2024. PMID: 38311354 Free PMC article.
-
Efficacy and Safety of Remimazolam in Short Endoscopic Procedures: A Systematic Review and Meta-Analysis.Medicina (Kaunas). 2025 Mar 5;61(3):453. doi: 10.3390/medicina61030453. Medicina (Kaunas). 2025. PMID: 40142264 Free PMC article.
-
Profile of Remimazolam in Anesthesiology: A Narrative Review of Clinical Research Progress.Drug Des Devel Ther. 2022 Oct 3;16:3431-3444. doi: 10.2147/DDDT.S375957. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36213379 Free PMC article. Review.
-
Remimazolam: An Updated Review of a New Sedative and Anaesthetic.Drug Des Devel Ther. 2022 Nov 15;16:3957-3974. doi: 10.2147/DDDT.S384155. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36411859 Free PMC article. Review.
References
REFERENCES
-
- Yu J, Xiang B, Song Y, et al. ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. Basic Clin Pharmacol Toxicol. 2019;125(5):460-465.
-
- Wesolowski AM, Zaccagnino MP, Malapero RJ, et al. Remimazolam: pharmacologic considerations and clinical role in anesthesiology. Pharmacotherapy. 2016;36(9):1021-1027.
-
- Bingol Tanriverdi T, Koceroglu I, Devrim S, Gura Celik M. Comparison of sedation with dexmedetomidine vs propofol during hysteroscopic surgery: single-centre randomized controlled trial. J Clin Pharm Ther. 2019;44(2):312-317.
-
- Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol. 2020;33(4):506-511.
-
- Borkett KM, Riff DS, Schwartz HI, et al. A Phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth Analg. 2015;120(4):771-780.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources